Fig. 4
NMZ treated E4FAD mice show improvements in Aβ pathology and synaptic biomarkers. Male E4FAD (n = 8–12) mice treated with NMZ for 12 weeks (1 mg/kg, i.p. + 20 mg/kg/day p.o.) showed attenuated formation of insoluble and soluble Aβ1–42 (a) and oligomeric Aβ (b) in hippocampal homogenates measured by ELISA. NMZ treatment led to elevated pCREB in the hippocampal fraction (c) without a change in total CREB determined by western blot. NMZ treated mice restored levels of the synaptic marker PSD-95 determined by western blot (d). Data show mean ± S.E.M. compared to the vehicle control. Statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001 and were analyzed by unpaired student’s t-test